SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on November 12, 2009 at $46.45. In approximately 3 months, Biogen Idec has returned Read More >>

Neurocrine Biosciences, a biopharmaceutical company, has appointed William Rastetter to its board of directors.

Dr Rastetter is the current chairman Read More >>

Biogen Idec Inc (NASDAQ: BIIB) said it expects 2010 earnings to be above $4.55 per share. The current consensus earnings estimate is Read More >>

Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of Read More >>

(Comment on this article at http://www.financialwire.net/2010/02/09/conference-calls-today-830-a-m-est-5/)

February 9, 2010 (FinancialWire) (Inve Read More >>

Biogen Idec (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of inn Read More >>

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has appointed William H. Rastetter Ph.D. to its Board of Directors effective Read More >>

                                  % Change

                        ------------------------------

Index          Close          Week  
          
            Read More
            >>
          
        

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, February 9th and determining how the Read More >>

Research and Markets (http://www.researchandmarkets.com/research/0d6475/partnering_agreeme) has announced the addition of the "Partnering Agr Read More >>

Research and Markets (http://www.researchandmarkets.com/research/bff085/partnering_agreeme) has announced the addition of the "Partnering Agreement Read More >>

SmarTrend's candlestick pattern scanner detected a bearish inside day candle pattern for shares of Biogen Idec (NASDAQ:BIIB). Yesterday Read More >>

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of Read More >>

Biogen Idec said that it has received notice from Icahn Partners and certain of its affiliates of their intention to nominate three individuals, Thomas F Read More >>

CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) announced the appointment of Nils Bergenhem, Ph.D., as its new Chief Scientific Officer, effective Read More >>

SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on November 12, 2009 at $46.45. In approximately 3 months, Biogen Idec has returned Read More >>

Biogen Idec (BIIB)

Expected next earnings release:

Announcement date: 2/9/2010 - Before Market

Earnings Quarter: Q4

Announcement St
          
            Read More
            >>
          
        

Biogen Idec (BIIB)

Expected next earnings release:

Announcement date: 2/9/2010 - Before Market

Earnings Quarter: Q4

Announcement St
          
            Read More
            >>
          
        

Research and Markets(http://www.researchandmarkets.com/research/aaf0d1/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Read More >>

Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio company CureTech Ltd. today announced that the first patient ha Read More >>

Smokefree Innotec, Inc. (PINKSHEETS: SFIO); Biogen Idec (NASDAQ: BIIB)

TheWallStreetLeader.com is part of Stock Profiler.US, LLC's New Read More >>

Biogen Idec (NASDAQ: BIIB) today announced it has received notice from Icahn Partners LP and certain of its affiliates of their int Read More >>

The FDA has approved Acorda's Ampyra for the symptomatic treatment of multiple sclerosis, making it the first therapeutic option approved to address walking Read More >>

25 January 2010 - Swedish Orphan Biovitrum (STO: BVT) and Biogen Idec (Nasdaq: BIIB) said today that the first patient

was dosed in an open-label Read More >>

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today reported positive results from a comparative study in primates of its longer-actin Read More >>

Cambridge, Mass. and Stockholm, Sweden - January 25, 2010 - Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: BVT) today ann Read More >>

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: BVT) today announced that the first patient w Read More >>

Biogen Idec (NASDAQ: BIIB) today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FD Read More >>

SmarTrend identified an Uptrend for Biogen Idec (NASDAQ:BIIB) on November 12, 2009 at $46.45. In approximately 2 months, Biogen Idec has returned Read More >>

Integrated Project Services (IPS), a leading, full-service engineering, construction, commissioning and qualification company dedicated Read More >>

Constellation Pharmaceuticals, Inc. today announced that it has appointed Garen Bohlin as the company's Executive Vice President. Mr. Read More >>

Biogen Idec (BIIB)

Expected next earnings release:

Announcement date: 2/9/2010 - Before Market

Earnings Quarter: Q4

Announcement St
          
            Read More
            >>
          
        

Biogen Idec (BIIB)

Expected next earnings release:

Announcement date: 2/9/2010 - Before Market

Earnings Quarter: Q4

Announcement St
          
            Read More
            >>
          
        

Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and full year 2009 financial results on Tuesday, February 9, Read More >>

Biogen Idec has submitted a marketing authorization application, or MAA, to the European Medicines Agency for Fampridine prolonged release tablets, an oral Read More >>

Trillium Therapeutics, a biopharmaceutical company, has entered into a definitive licensing agreement with Biogen Idec, granting the latter exclusive worldw Read More >>

Las Vegas CRWENews.com is pleased to announce a stock highlight on Biogen Idec Inc. In a presentation to investors today at the 28th Annual J.P. Morgan Hea Read More >>

Zacks Equity Research highlights Whirlpool Corporation (NYSE: WHR) as the Bull of the Day and SIRIUS XM Radio (Nasdaq: SIRI) the Bea Read More >>

Lycera, a pharmaceutical company focused on developing small-molecule medicines to treat autoimmune diseases, announced that William J. Sibold has been n Read More >>

Lycera Corp., a pharmaceutical company focused on developing novel small-molecule medicines to treat autoimmune diseases, announced that William J. Sibol Read More >>

Trillium Therapeutics, Inc., a Canada-based biopharmaceutical company, has entered into a definitive license agreement with Biogen I Read More >>

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a commu Read More >>

Today, shares of Biogen Idec (NASDAQ:BIIB) have crossed bullishly above their 10-day moving average of $53.57 on volume of 328 thousand Read More >>

Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that it has en Read More >>

Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entere Read More >>

--Pipeline Continues to Advance, Including Fampridine EU Filing

In a presentation to investors today at the 28th Annual J.P. Morgan He Read More >>

Biogen Idec (NASDAQ: BIIB) announced today the submission of a marketing authorization application (MAA) to the European Medicines Agency f Read More >>

Baron Baptiste, bestselling author and founder of Baptiste Power Vinyasa Yoga, and Dr. Elliot Frohman, one of the world's leading authoriti Read More >>

Biogen Idec (BIIB)

Expected next earnings release:

Announcement date: 2/4/2010 - Before Market

Earnings Quarter: Q4

Announcement St
          
            Read More
            >>